Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients

Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients

Abstract Intensive care unit (ICU) admissions and mortality in severe COVID-19 patients are driven by “cytokine storms” and acute respiratory distress syndrome (ARDS). Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 pati...

Full description

Bibliographic Details
Main Authors: Samir Awasthi, Tyler Wagner, A. J. Venkatakrishnan, Arjun Puranik, Matthew Hurchik, Vineet Agarwal, Ian Conrad, Christian Kirkup, Raman Arunachalam, John O’Horo, Walter Kremers, Rahul Kashyap, William Morice, John Halamka, Amy W. Williams, William A. Faubion, Andrew D. Badley, Gregory J. Gores, Venky Soundararajan
Format: Article
Language:English
Published: Nature Publishing Group 2021-03-01
Series:Cell Death Discovery
Online Access:https://doi.org/10.1038/s41420-021-00429-9

Internet

https://doi.org/10.1038/s41420-021-00429-9

Similar Items